Project: GT-002 for the treatment of schizophrenia.
The aim is to advance a new drug candidate (GT-002) through Phase 1 clinical studies in healthy volunteers for later development of clinical proof of concept in the treatment of schizophrenia. Healthy male volunteers will first be administered GT-002 in a Single Ascending Dose (SAD) study, combined with assessment of food effects on absorption, followed by a Multiple Ascending Dose (MAD) study. Additional single-dose studies will confirm target engagement with PET imaging and EEG analysis.
| Acronym | GASH02 (Reference Number: 10687) |
| Duration | 01/03/2016 - 01/03/2019 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 5 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 24910 | Smerud Medical Research International AS | Coordinator | Norway |
| 24911 | Gabather AB | Partner | Sweden |
| 24912 | Pharmaterials Ltd. | Partner | United Kingdom |
| 24913 | Clinical Research Services Turku CRST | Partner | Finland |